COMPARE PEPTIDES

See how peptides differ.

Compare up to three compounds. See their targets, study limits, and original sources side by side.

Column 1

Column 2

Column 3

Scroll sideways to see all the compounds.

Peptide

Metabolic

Semaglutide

GLP-1 analog

Metabolic

Tirzepatide

GIP GLP-1 co-agonist

Metabolic

Retatrutide

LY3437943

Evidence availableResearch type and stage

Evidence availableEvidence for a defined medicine

Evidence availableHuman studies exist

Molecular identityReported length or form

Peptide length: 31 amino acids

Peptide length: 39 amino acids

Peptide length: 39 amino acids

Research target

GLP-1 receptor

Incretin analog

GIP and GLP-1 receptors

Dual incretin agonist

GIP, GLP-1 and glucagon receptors

Multi-receptor incretin analog

Molecular form

Acylated peptide analog

C187H291N45O59

Acylated peptide analog

C225H348N48O68

Acylated peptide analog

Evidence notesWhat the studies cover

Use the current label for the exact product and population. A trial of a finished medicine does not establish equivalence for a research vial or semaglutide salt.

Distinguish diabetes, weight-management and obstructive-sleep-apnea evidence. Receptor activity alone does not predict comparative clinical outcomes.

Interpret weight changes with trial duration, escalation, discontinuations and comparator in view. Consult the trial register for subsequent development.

Identity checks

Confirm the modified sequence, acylation, counterion and formulation. Semaglutide base and salt forms must not be treated as interchangeable.

Check the full modified structure and lipid side chain. A backbone length or purity percentage does not establish pharmaceutical equivalence.

Distinguish the studied molecule from other triple agonists and from commercially described salts or research preparations.

Original sources

FDA: semaglutide shortage determination (2025)FDA: Wegovy prescribing information (2026)PubChem CID 56843331

FDA: Zepbound obstructive sleep apnea approval PubChem CID 156588324

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

Check what each study tested. Compounds in the same category can have different structures and evidence. Results for one formulation or study setting may not apply to another.

Keep this comparison close.

Get these compounds, their evidence notes, original sources, and a comparison checklist in one pack. Your selections carry over.

Get my research pack